Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out drugs are emerging.
Boston Scientific Corp. (BSX) announced positive three-year primary endpoint results from the OPTION global clinical trial of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback